Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking ...

March 7, 2025 /PRNewswire/ -- Four new officers and four new board members will be installed immediately upon conclusion of the 2025 Annual Meeting of the American Academy of Dermatology.

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are ...

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...

Recent refinements to a multiphase approach to delusional infestations make this treatment protocol effective even within a ...

Q32 Bio (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia ...

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

Larry Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children's Hospital, presented a session at ...

Four new officers and four new board members will be installed immediately upon conclusion of the 2025 Annual Meeting of the American Academy of Dermatology. The officers and board members are all ...